Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) (“Evotec”) to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec’s undisturbed share price on October 15, 2024, the day prior to Triton Partners’ initial accumulation of Evotec shares, and a premium of 77% to Evotec’s last three-month volume weighted average price on October 15, 2024.
Read the full article: Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction //
Source: https://www.prnewswire.com/news-releases/halozyme-confirms-proposal-to-combine-with-evotec-for-11-00-per-share-in-an-all-cash-transaction-302306384.html